People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of…
Articles by Marta Figueiredo, PhD
Switching from the approved Tyvaso (inhaled treprostinil) nebulizer to Tyvaso DPI — an investigational dry-powder formulation — is safe, effective,…
Researchers have identified a new mutation in the FLNA gene that was linked with pulmonary arterial hypertension (PAH) and congenital…
Long-term treatment with Bayer’s Adempas (riociguat) was safe and well-tolerated in people with pulmonary arterial hypertension (PAH), according…
The first wave of COVID-19Â in Europe severely disrupted access to care and raised stress and anxiety in people with…
Acceleron Pharma announced plans to launch the first Phase 3 clinical trial, called STELLAR, evaluating the safety and effectiveness…
Suppressing CD248, a cell surface protein, reduced pulmonary vascular remodeling — the key structural alteration in pulmonary arterial hypertension (PAH)…
Mallinckrodt Pharmaceuticals’ INOmax (nitric oxide) gas improves oxygenation in premature newborns with pulmonary hypertension (PH) at least…
People with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — particularly those showing low or intermediate disease risk, typical…
Oral delivery of two proteins produced on lettuce leaves and involved in blood vessel health eased pulmonary hypertension and…
Blood levels of uric acid may be a predictive biomarker of pulmonary arterial hypertension (PAH) in people…
Riociguat increases the risk of death and serious adverse events in people with pulmonary hypertension (PH) associated with idiopathic interstitial …